Seagen Inc. v. Daiichi Sankyo Company, Ltd., No. 23-2424 (Fed. Cir. Dec. 2, 2025)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

A jury in the United States District Court for the East- ern District of Texas found that claims 1 –5, 9, and 10 of Seagen Inc.’s (“Seagen”) U.S. Patent 10,808,039 (“the ’039 patent”) were not invalid for lack of written description or enablement. J.A. 57. The jury further found that Daichii Sankyo Company, Ltd. AstraZeneca Pharmaceuticals LP, and AstraZeneca UK Ltd., (collectively, “Daichii”) willfully infringed at least one of the claims , and awarded Seagen damages exceeding $41 million . J.A. 56, 58–59.